References
- American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009
- Jansman FGA, Postma MJ, Brouwers JRBJ. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 2007;25:537-62
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer; 2008. Available at: www.nccn.org. Last accessed July 1, 2010
- Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-60
- Pasetto LM, Jirillo A, Iadicicco G, et al. FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 2005;25:563-76
- Hillner BE, Schrag D, Sargent DJ, et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005;104:1871-84
- Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated health care costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia. Pharmacoeconomics 2007;25:481-96
- US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999–2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics, 2008. http://data.bls.gov/cgi-bin/surveymost?su
- Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Manning W, Mullahy J. Estimation log models: to transform or not to transform? J Health Econ 2001;20:461-94
- Owens D. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998;13:716-17
- Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
- Tournigand C, Andrè T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
- Tumeh JW, Shenoy PJ, Moore SG, et al. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. Am J Clin Oncol 2009;32:49-55